Infigratinib is a selective tyrosine kinase inhibitor primarily utilized as an epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer characterized by EGFR exon 20 insertion… Read more
Infigratinib is a selective tyrosine kinase inhibitor primarily utilized as an epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer characterized by EGFR exon 20 insertion mutations. Laboratories working with this compound require high-quality Infigratinib reference standards and related impurities to support accurate impurity profiling and rigorous quality control protocols during pharmaceutical manufacturing. Identifying and quantifying impurities like N1-nitroso, N2-nitroso, and N1,N2-dinitroso derivatives is essential for ensuring compliance with regulatory safety guidelines and validating analytical methods. Furthermore, the inclusion of stable isotope labelled compounds, such as Infigratinib-d6, provides critical internal standards for mass spectrometry-based assays, enabling precise quantification of the drug substance in complex biological matrices. These analytical tools allow for the reliable detection and monitoring of critical components throughout the drug development and method validation lifecycle.